Drug Trial Radar · NCT03321981
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Last checked: Nov 20, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jan 15, 2018
Primary completion
Oct 26, 2022
Study completion Jul 26, 2023
Sponsor
- Lead sponsor
- Merus B.V.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2. MCLA-128 (zenocutuzumab) is given in combinations in two metastatic breast cancer (MBC) populations, Human Epidermal Growth Factor Receptor (HER) 2-positive/amplified (Cohort 1) and Estrogen Receptor-positive/low HER2 expression (Cohort2). Two combinations treatments will be evaluated in Cohort 1, the doublet and triplet. Initially zenocutuzumab is given in combination with trastuzumab in the doublet. After the safety of the doublet has been assessed in 4-6 patients, MCLA-128 is given in combination with trastuzumab and vinorelbine in the triplet, in parallel to the efficacy expansion of the doublet. The doublet and triplet combinations are both evaluated in two steps with an initial safety run-in followed by a cohort efficacy expansion. In total up to 40 patients evaluable for efficacy are included in both the doublet and triplet. In Cohort 2 zenocutuzumab is administered in combination with the same previous endocrine therapy on which progressive disease is radiologically documented. A total of up to 40 patients evaluable for efficacy are included in the Cohort 2.
Conditions
- Breast Cancer Metastatic
Interventions
ZenocutuzumabDrug
full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3
TrastuzumabDrug
humanised IgG1 monoclonal antibody
VinorelbineDrug
antineoplastic drug of vinca alkaloid family
Endocrine therapyDrug
same endocrine therapy is administered as the last line of endocrine therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Benefit Rate at 24 WeeksTime frame: 24 weeks
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
HCA Midwest Health
Kansas City, Kansas
Sarah Cannon Research Institute
Nashville, Tennessee
Institut Jules Bordet
Brussels, Belgium
Grand Hôpital de Charleroi (GHdC)
Charleroi, Belgium
UZ Leuven
Leuven, Belgium
Hôpital Jean Minjoz
Besançon, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Georges-Francois Leclerc
Dijon, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmette
Marseille, France
Centre René Huguenin
Saint-Cloud, France
Centre Paul Strauss
Strasbourg, France
Centre Claudius Régaud
Toulouse, France
Institute Gustave Roussy
Villejuif, France
Netherlands Cancer Institute NKI
Amsterdam, North Holland, Netherlands
Champalimaud Clinical Centre
Lisbon, Portugal
Hopistal San Antonio
Porto, Portugal
Instituto Português Oncologia
Porto, Portugal
Vall D'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Hospital Clinic. C/Villaroel
Barcelona, Spain
Ramon Y Cajal Universitary Hospital
Madrid, Spain
Hospital Universitario 12de Octubre
Madrid, Spain
Instituto Valenciano de Oncologia
Valencia, Spain
Sarah Cannon Research Institute UK
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.